On the contrary, the 12 centers with the ‘non-compliant group’ we

On the contrary, the 12 centers with the ‘non-compliant group’ were only recently developed. Although they are capable of providing GSK126 solubility dmso haemophilia treatment, they

lack the appropriate comprehensive care team members with the necessary expertise to guide the patients to overcome their difficulties (logistics, expectations, economical problems etc.) and to oversee the proper conduct of the prophylaxis protocol and trial. Overcoming the obstacles in compliance to prophylaxis in China will require a multi-prone approach. (i) Fundamentally, we need to make sure that factor concentrates are affordable and available. A number of economically advantaged Chinese cities are beginning to provide medical insurance to partially cover concentrate purchase and it is anticipated that with the rapid economical growth in expanding regions of China, medical insurance for haemophilia care will eventually become more widespread in China. (ii) To promote prophylaxis, we need to establish many more haemophilia treatment centers

and these centers will selleck compound need to have their infrastructure and comprehensive care team well developed. Currently, there are additional 18 newly established HTCCNC members (in addition to the original six; [4]) in China and the expectation is that within 5 years, there will be at least one haemophilia treatment center in each of the 31 provinces and 4 centrally governed administrative districts. The original six HTCCNC founding members have been designated by the World Federation of Hemophilia (WFH) through the GAP (Global Alliance for Progress) Program as WFH China Hemophilia Training Centers for training these new centers. It can therefore be expected that these new centers will be among the next ones to develop into full-fledge comprehensive haemophilia care center in the near future. (iii) The individual comprehensive care team and the ‘training/teaching centers’

must provide appropriate education to patients/parents and other health-care workers to promote the concept of haemophilia preventative care, of which prophylaxis is a major aspect. The most important finding in this multicenter pilot study is its confirmation that low-dose secondary prophylaxis even MCE in short-term does provide substantial benefits in controlling haemorrhage and improving daily activities/function without increasing consumption of factors in China. Our study clearly established that low-dose prophylaxis can be provided efficiently in a number of more ‘matured’ haemophilia treatment centers, provided clotting factors are available and affordable and that a multidisciplinary comprehensive haemophilia care team is present. We also identified that there are currently obstacles to providing prophylaxis more widely in China.

Comments are closed.